Charles River Laboratories Research and Development Expenses 2010-2024 | CRL

Charles River Laboratories annual/quarterly research and development expenses history and growth rate from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
  • Charles River Laboratories research and development expenses for the quarter ending June 30, 2024 were $M, a NAN% increase year-over-year.
  • Charles River Laboratories research and development expenses for the twelve months ending June 30, 2024 were $0M, a NAN% increase year-over-year.
  • Charles River Laboratories annual research and development expenses for 2023 were $0B, a NAN% decline from 2022.
  • Charles River Laboratories annual research and development expenses for 2022 were $0B, a NAN% decline from 2021.
  • Charles River Laboratories annual research and development expenses for 2021 were $0B, a NAN% decline from 2020.
Charles River Laboratories Annual Research and Development Expenses
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $
2009 $
Charles River Laboratories Quarterly Research and Development Expenses
(Millions of US $)
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical Services $11.042B $4.129B
Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
Stock Name Country Market Cap PE Ratio
Elevance Health (ELV) United States $95.766B 11.88
Cencora (COR) United States $49.023B 18.08
DiDi Global (DIDIY) China $23.330B 0.00
ICON (ICLR) Ireland $17.511B 15.60
Natera (NTRA) United States $16.712B 0.00
Viatris (VTRS) United States $15.433B 4.75
Avantor (AVTR) United States $14.831B 22.24
Revvity (RVTY) United States $14.647B 25.44
BioMerieux (BMXMF) France $12.894B 0.00
CochLear (CHEOY) Australia $12.739B 0.00
Solventum (SOLV) United States $12.214B 0.00
Medpace Holdings (MEDP) United States $11.215B 31.59
Doximity (DOCS) United States $10.778B 63.79
HealthEquity (HQY) United States $8.750B 47.49
Sonic Healthcare (SKHHY) Australia $8.450B 0.00
Bausch + Lomb (BLCO) Canada $6.881B 32.03
Life Times (LTH) United States $5.005B 33.12
Sotera Health (SHC) United States $4.402B 23.55
Organon (OGN) United States $4.012B 4.05
Surgery Partners (SGRY) United States $3.759B 42.85
BrightSpring Health Services (BTSG) United States $3.402B 72.37
PACS (PACS) United States $3.129B 0.00
Concentras Parent (CON) United States $2.579B 0.00
Alignment Healthcare (ALHC) United States $2.523B 0.00
Ardent Health Partners (ARDT) United States $2.446B 0.00
Premier (PINC) United States $2.301B 11.48
GeneDx Holdings (WGS) United States $2.113B 0.00
Ryman Healthcare (RYHTY) New Zealand $2.036B 0.00
GoodRx Holdings (GDRX) United States $1.783B 47.00
Teladoc Health (TDOC) United States $1.670B 0.00
Progyny (PGNY) United States $1.551B 29.62
Pediatrix Medical (MD) United States $1.331B 13.02
CareDx (CDNA) United States $1.251B 0.00
Establishment Labs Holdings (ESTA) $1.184B 0.00
AMN Healthcare Services Inc (AMN) United States $0.993B 6.72
Embecta (EMBC) United States $0.898B 5.99
QDM (QDMI) Hong Kong, SAR China $0.790B 20.69
InnovAge Holding (INNV) United States $0.778B 0.00
Agilon Health (AGL) United States $0.770B 0.00
SBC Medicals (SBC) United States $0.717B 0.00
Auna S.A (AUNA) Luxembourg $0.510B 0.00
Sonida Senior Living (SNDA) United States $0.442B 0.00
DocGo (DCGO) United States $0.426B 16.00
Enhabit (EHAB) United States $0.383B 33.09
COMPASS Pathways (CMPS) United Kingdom $0.346B 0.00
LifeMD (LFMD) United States $0.310B 0.00
ModivCare (MODV) United States $0.244B 13.24
Sera Prognostics (SERA) United States $0.242B 0.00
Beauty Health (SKIN) United States $0.211B 0.00
Nutex Health (NUTX) United States $0.204B 0.00
Biodesix (BDSX) United States $0.204B 0.00
MultiPlan (MPLN) United States $0.141B 0.00
Ascend Wellness Holdings (AAWH) United States $0.120B 0.00
So-Young (SY) China $0.073B 17.77
Singular Genomics Systems (OMIC) United States $0.057B 0.00
Harvard Apparatus Regenerative Technology (HRGN) United States $0.054B 0.00
OncoCyte (OCX) United States $0.051B 0.00
NeueHealth (NEUE) United States $0.042B 1.12
Co-Diagnostics (CODX) United States $0.037B 0.00
Pheton Holdings (PTHL) China $0.029B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.027B 0.00
IceCure Medical (ICCM) Israel $0.027B 0.00
Oncology Institute (TOI) United States $0.022B 0.00
SeaStar Medical Holding (ICU) United States $0.012B 0.00
XWELL (XWEL) United States $0.009B 0.00
Intelligent Bio Solutions (INBS) United States $0.009B 0.00
BioNexus Gene Lab (BGLC) $0.006B 0.00
KindlyMD (KDLY) United States $0.005B 0.00
ISpecimen (ISPC) United States $0.004B 0.00
NewGenIvf Group (NIVF) Thailand $0.003B 0.00
Aclarion (ACON) United States $0.002B 0.00
Cano Health (CANOQ) United States $0.001B 0.00